Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Myhep All - 12 weeks

HepatitisC-Mylan-Velpatasvir-100mg-Sofosbuvir-400mg-Myhep-ALL

Availability: In stock

Special Price $ 1599

BRAND : Myhep All
STRENGTH : 400 mg & 100 mg
INGREDIENT : HepatitisC-Mylan-Velpatasvir-100mg-Sofosbuvir-400mg-Myhep-ALL
COMPANY NAME : Mylan
COUNT : 28 Tablets



Description of Myhep All - 12 weeks

Brand name: Myhep All Active component: Sofosbuvir and Velpatasvir Strength of the components: 400mg and 100mg respectively Mfg: Mylan Package: 28 tablets in a container Category: Anti-viral agent Description – 12 weeks Myhep All is a prescription medicine; it is taken by the patients only under the guidance of medical practitioner Myhep All is a fixed dose combination drug, contains Sofosbuvir and Velpatasvir as an active ingredients. Both the components exhibit anti-viral activity. Myhep All tablet is active against virus which causes hepatitis C infection in adults Myhep All contains; Sofosbuvir-HCV NS5B polymerase inhibitor Velpatasvir-HCV NS5A inhibitor

Pharmacology of Myhep All - 12 weeks

Mechanism of action: 12 weeks Myhep All – Treatment for chronic hepatitis C viral infection for 12 weeks Velpatasvir HCV NS5A protein inhibitor, it blocks the protein activity and inhibits viral multiplication. Sofosbuvir is one of the component of Myhep All tablet, is an HCV NS5B RNA polymerase inhibitor This undergoes intracellular metabolism to form uridine analogue triphosphate Inhibition of viral multiplication occurs by incorporating into HCV RNA and acts as a chain terminator Pharmacokinetic: 12 weeks Absorption: The Myhep All tablet was quickly absorbed after oral administration. The peak plasma concentration of both component in Myhep All and active metabolite of Myhep All (GS-461203) occurs within 1 hour, 3 hours, and 3 hours respectively Distribution: Food does not interfere with Myhep All action Sofosbuvir, Plasma protein binding: 61-65% Velpatasvir, plasma protein bound: >99.5% The active metabolite of the tablet Myhep All has poor protein binding property. Metabolism: Sofosbuvir is metabolized in liver, changed to active analogue triphosphate GS-461203 Elimination: 80% metabolite eliminated: urine; 14% of metabolites: faeces; 2.5%: exhaled air The terminal half life of Myhep All tablet is 15 hours

Indication of Myhep All - 12 weeks

Myhep All is mainly indicated for the patients who are suffered with chronic hepatitis C viral infection associated genotype I, II, III, IV, V or VI infection. Generally Myhep All tablets are taken for 12 weeks, it may effective in patients. Types of hepatitis Without cirrhosis or with compensated cirrhosis With decompensated cirrhosis with use of ribavirin

Dose & Dosage's of Myhep All - 12 weeks

Myhep All is recommended for adults. The safety and efficacy of the drug has not been established for children. Chronic hepatitis C virus (HCV) infection genotypes I, II, III, IV, V or VI One tablet to be taken as a single dose Myhep All should be taken with or without food The usual dose of Myhep All is one tablet to be taken orally as a single dose Therapy naïve and therapy experienced, without cirrhosis: Myhep All should be taken for 12 weeks Decompensated cirrhosis: Myhep All combined with ribavirin followed for 12 weeks The dose of ribavirin recommended on the basis of weight of patient; <75 kg: 1000mg/day twice daily ≥75 kg: 1200mg/day twice daily The dosage of ribavirin should be decreased on the basis of hemoglobin and creatine clearance levels. Missed dose: If patient missed the dose of Myhep All tablet, should be skipped and follow the next dose schedule Do not take double dose

Side Effects of Myhep All - 12 weeks

Patients Without cirrhosis Headache, fatigue, shortness of breath, chest pain Patients With decompensated cirrhosis Fatigue, anemia, decreased hemoglobulin levels, nausea, headache, insomnia 1-10% of patients attain; Patients Without cirrhosis; Lipase increase, rash, depression, increased creatine kinase, insomnia, asthenia Patients With decompensated cirrhosis; Diarrhea, hemoglobin levels get depleted, rash, increased creatine kinase Common side effects: Headache, unusual tiredness, chest pain, swelling of peripheral organs, skin rashes, breathing trouble Post marketing reports: angioedema

Contraindication of Myhep All - 12 weeks

Myhep All while combining with ribavirin for advanced cirrhosis, in this condition it is contraindicated to the pregnant women and women who become pregnant, ribavirin cause harm to the fetal

Drug Interaction of Myhep All - 12 weeks

While taking Myhep All for 12 weeks, some of the drugs should not take in combination; Ant acids: aluminium hydroxide, magnesium hydroxide, calcium carbonate H2 receptor antagonist: famotidine, ranitidine, Cimetidine Proton pump inhibitors: Omeprazole, esomeprozole, pantoprazole, lansoprazole Anti-arrhythmic: amiodarone, digoxin Anti-cancer: topotecan Anti-mycobacterials: rifabutin, rifampin, rifapentine HIV antiretroviral: efavirenz, tenofovir, tipranavir ritonavir Herbal supplements: st. Johns wort Anti convulsants: carbamazepine, phenytoin, Phenobarbital, oxcarbazepine HMG CoA reductase inhibitors: rosuvastatin, Atorvastatin

Precaution of Myhep All - 12 weeks

Risk of HBV reactivation in patient co infected with HCV and HBV Co administration of amiodarone with Myhep All causes bradycardia; caution should be taking while combining with amiodarone Caution with use in Liver and kidney impairment patients

Usage & Safety profile of Myhep All - 12 weeks Pregnancy & Lactation

Myhep All with ribavirin is not safe to use in pregnancy condition, it may leads to fetal death Breast feeding is not recommended

Storage of Myhep All - 12 weeks

Myhep All should be stored at room temperature. Myhep All container should be keep away from moisture, heat, and light